Inoue H - Search Results

1

Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.

Yamagishi S, Nakamura K, Inoue H. Yamagishi S, et al. Among authors: inoue h. Med Hypotheses. 2005;65(6):1013-5. doi: 10.1016/j.mehy.2005.07.017. Med Hypotheses. 2005. PMID: 16146671

2

Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.

Yamagishi S, Takeuchi M, Inoue H. Yamagishi S, et al. Among authors: inoue h. Drugs Exp Clin Res. 2005;31(2):45-51. Drugs Exp Clin Res. 2005. PMID: 15929605

3

Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.

Yamagishi S, Takeuchi M, Inoue H. Yamagishi S, et al. Among authors: inoue h. Int J Tissue React. 2005;27(3):137-43. Int J Tissue React. 2005. PMID: 16372480

4

A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.

Yamagishi S, Nakamura K, Matsui T, Inoue H. Yamagishi S, et al. Among authors: inoue h. Med Hypotheses. 2007;69(2):338-40. doi: 10.1016/j.mehy.2006.11.054. Epub 2007 Feb 27. Med Hypotheses. 2007. PMID: 17329034

5

Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.

Yamagishi S, Nakamura K, Matsui T, Inoue H, Takeuchi M. Yamagishi S, et al. Among authors: inoue h. Med Hypotheses. 2007;69(3):666-8. doi: 10.1016/j.mehy.2006.12.045. Epub 2007 Feb 28. Med Hypotheses. 2007. PMID: 17331665

6

Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells.

Matsui T, Yamagishi S, Nakamura K, Inoue H, Takeuchi M. Matsui T, et al. Among authors: inoue h. J Int Med Res. 2007 Jan-Feb;35(1):107-12. doi: 10.1177/147323000703500111. J Int Med Res. 2007. PMID: 17408061 Free article.

7

Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.

Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H. Matsui T, et al. Among authors: inoue h. J Int Med Res. 2007 Jul-Aug;35(4):482-9. doi: 10.1177/147323000703500407. J Int Med Res. 2007. PMID: 17697525 Free article.

8

Met72Thr polymorphism of pigment epithelium-derived factor gene and susceptibility to age-related macular degeneration.

Yamagishi S, Nakamura K, Inoue H, Takeuchi M. Yamagishi S, et al. Among authors: inoue h. Med Hypotheses. 2005;64(6):1202-4. doi: 10.1016/j.mehy.2005.01.017. Med Hypotheses. 2005. PMID: 15823717

9

Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.

Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Yamagishi S, et al. Among authors: inoue h. Med Hypotheses. 2005;64(6):1205-7. doi: 10.1016/j.mehy.2005.01.016. Med Hypotheses. 2005. PMID: 15823718

10

Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.

Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Yamagishi S, et al. Among authors: inoue h. Med Hypotheses. 2005;64(6):1208-10. doi: 10.1016/j.mehy.2005.01.015. Med Hypotheses. 2005. PMID: 15823719

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,547 results

Search Page

Filters